GO:0016516 interleukin-4 receptor complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016516 (interleukin-4 receptor complex) is a cell-surface protein complex that binds IL-4 and consists of a high-affinity IL-4Rα chain plus the common gamma chain (γc) shared with the IL-2 receptor.
• The complex exists in two principal forms: a type I receptor (IL-4Rα/γc) and a type II receptor (IL-4Rα/IL-13Rα1) that also binds IL-13.
• Assembly is driven by ligand binding: IL-4 engages IL-4Rα first, then recruits γc or IL-13Rα1 to form a signaling-competent ternary complex.
• Signaling through the complex activates JAK/STAT6, IRS-1/2 and other pathways that control Th2 differentiation, IgE class switching, macrophage polarization and tissue remodeling.
• Dysregulated IL-4 receptor complex activity is implicated in asthma, atopic dermatitis, fibrosis, cholangiocyte dysfunction and adverse cardiac remodeling.
• The complex is a validated drug target: dupilumab blocks IL-4Rα and is approved for Th2-driven inflammatory diseases.
Description
The interleukin-4 receptor complex (GO:0016516) is the cell-surface protein assembly that binds the cytokine interleukin-4 (IL-4) and initiates its biological effects. According to the Gene Ontology, it consists of an alpha chain that binds IL-4 with high affinity and a gamma common chain that also forms part of the interleukin-2 receptor. This architecture places the complex at the center of type 2 immune responses, linking cytokine recognition to JAK/STAT signaling and downstream transcriptional programs. Because IL-4 and IL-13 share receptor components, the complex also serves as a node of cytokine pleiotropy, explaining why a single receptor can mediate overlapping and distinct functions. Researchers study GO:0016516 to understand allergic inflammation, macrophage biology, tissue repair and cancer immunology, and to design biologics that selectively interrupt these pathways. The complex is therefore both a fundamental cell-biology entity and a clinically actionable target.
interleukin-4 receptor complex At A Glance
| GO ID | GO:0016516 |
|---|---|
| GO term | interleukin-4 receptor complex |
| Ontology | cellular_component |
| Synonym | IL-4 receptor complex |
| Major function | Binds IL-4 with high affinity and transduces signals via associated JAK kinases and STAT6 |
| Subunit composition | IL-4Rα plus either γc (type I) or IL-13Rα1 (type II) |
| Ligand specificity | IL-4; type II complexes also bind IL-13 |
| Cellular location | Plasma membrane of immune and non-immune cells |
| Shared subunits | γc is shared with the IL-2 receptor; IL-13Rα1 is shared with the IL-13 receptor |
What Is GO:0016516?
In the Gene Ontology, GO:0016516 (interleukin-4 receptor complex) is defined as a protein complex that binds interleukin-4 (IL-4) and consists of an alpha chain that binds IL-4 with high affinity and a gamma common chain that also forms part of the interleukin-2 receptor. In practice, this means the complex is a heteromeric cell-surface receptor: the IL-4Rα subunit provides high-affinity IL-4 binding, while the common gamma chain (γc) or the IL-13Rα1 subunit completes the signaling-competent assembly. The synonym IL-4 receptor complex is used interchangeably. The term is annotated to the cellular component aspect, reflecting its location at the plasma membrane and its role as a membrane receptor assembly.
Why Is interleukin-4 receptor complex Important in Cell Biology?
The interleukin-4 receptor complex is important because it converts a soluble cytokine signal into durable changes in cell state, including Th2 cell differentiation, alternative macrophage activation, B-cell class switching to IgE, goblet cell hyperplasia and fibroblast activation. These outputs are essential for host defense against helminths but become pathogenic in allergy, asthma and fibrosis. The complex is also expressed on non-immune cells such as cholangiocytes and cardiomyocytes, where it regulates ion transport and adverse remodeling. Because IL-4Rα is the high-affinity, ligand-specific subunit, it is a preferred target for therapeutic blockade, exemplified by dupilumab. Understanding GO:0016516 therefore connects basic cytokine biology to precision medicine.
• Defines the receptor assembly that initiates IL-4 signaling in T cells, B cells, macrophages and dendritic cells.
• Controls Th2 differentiation and IgE class switching, central to allergic disease.
• Mediates alternative macrophage activation and tissue remodeling.
• Type II complexes also respond to IL-13, linking IL-4 and IL-13 biology.
• Dysregulation is implicated in asthma, atopic dermatitis and fibrosis.
• Expressed on cholangiocytes where it regulates TMEM16A and biliary secretion.
• Expressed on cardiac macrophages where it drives adverse remodeling after ischemic injury.
• Provides a validated drug target for dupilumab and other IL-4Rα blockers.
• Serves as a model for cytokine receptor pleiotropy and shared subunit usage.
• Enables structure-guided design of inhibitors and biased ligands.
Structure and Composition of interleukin-4 receptor complex
IL-4Rα: the high-affinity ligand-binding subunit
In simple terms: IL-4Rα is the part of the receptor that grabs IL-4 tightly.
IL-4Rα is the alpha chain that binds IL-4 with high affinity and is the defining subunit of GO:0016516. It is a type I cytokine receptor with extracellular fibronectin type III domains, a transmembrane helix and an intracellular domain that recruits JAK kinases. Structural studies show that IL-4 engages IL-4Rα through a conserved cytokine-receptor interface, forming the initial binary complex that is a prerequisite for signaling. Because IL-4Rα is the ligand-specific subunit, it is the primary target of blocking antibodies such as dupilumab.
γc: the common gamma chain shared with the IL-2 receptor
In simple terms: γc is a helper subunit that the IL-4 receptor borrows from the IL-2 receptor.
The common gamma chain (γc) is the second subunit of the type I IL-4 receptor complex and is shared with the interleukin-2 receptor. After IL-4 binds IL-4Rα, γc is recruited to form a ternary complex that brings the intracellular JAK kinases into proximity, enabling trans-phosphorylation and downstream signaling. Because γc is shared by multiple cytokine receptors, mutations or competition at this subunit can broadly affect cytokine responses.
IL-13Rα1: the alternative subunit defining type II complexes
In simple terms: IL-13Rα1 can replace γc to make a receptor that also responds to IL-13.
A second form of the interleukin-4 receptor complex uses IL-13Rα1 instead of γc, forming the type II receptor that binds both IL-4 and IL-13. This type II complex is expressed on non-hematopoietic cells such as epithelial and stromal cells and mediates IL-13-driven responses in asthma and fibrosis. The existence of two complexes with different subunit compositions explains the pleiotropy of the IL-4/IL-13 system and provides opportunities for selective therapeutic targeting.
Assembly and stoichiometry
In simple terms: The receptor is built step by step when IL-4 arrives.
Assembly of GO:0016516 is ligand-driven: IL-4 first binds IL-4Rα to form a binary complex, which then recruits either γc or IL-13Rα1 to create a signaling-competent ternary complex. This ordered assembly ensures that signaling only occurs when the correct ligand is present and the appropriate partner subunit is available. The stoichiometry and geometry of the ternary complex determine which JAK kinases are activated and which STAT factors are recruited, thereby shaping the downstream response.
Key Genes Involved in GO:0016516 interleukin-4 receptor complex
The following genes encode the subunits, signaling kinases, adaptors and downstream effectors most closely associated with the interleukin-4 receptor complex (GO:0016516).
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL4R | Encodes IL-4Rα, the high-affinity IL-4-binding subunit of the complex | Primary target for knockout, point mutation and antibody-blockade studies |
| IL2RG | Encodes the common gamma chain (γc) shared with the IL-2 receptor | Knockout reveals shared cytokine signaling defects |
| IL13RA1 | Encodes IL-13Rα1, the alternative subunit of type II complexes | Knockout distinguishes type I vs type II signaling |
| JAK1 | Tyrosine kinase that associates with IL-4Rα and initiates signaling | Kinase-dead and point-mutant models probe signal initiation |
| JAK3 | Tyrosine kinase that associates with γc | Knockout models define γc-dependent signaling |
| STAT6 | Transcription factor activated downstream of the complex | Knockout is the standard readout for IL-4/IL-13 responses |
| IRS1 | Adaptor that couples the complex to PI3K/Akt signaling | Overexpression and knockout study metabolic arms |
| IRS2 | Adaptor that couples the complex to PI3K/Akt signaling | Knockout models probe alternative activation |
| IL4 | Ligand that binds and activates the complex | Overexpression and knock-in models drive type 2 inflammation |
| IL13 | Ligand that activates type II complexes | Knockout distinguishes IL-4 vs IL-13 effects |
| SOCS1 | Negative regulator of JAK/STAT signaling | Overexpression suppresses complex signaling |
| SOCS3 | Negative regulator of JAK/STAT signaling | Knockout enhances cytokine responses |
| PIK3CA | Catalytic subunit of PI3K downstream of IRS adaptors | Point mutations probe PI3K-dependent arms |
| AKT1 | Serine/threonine kinase downstream of PI3K | Overexpression and knockout study survival signals |
| TMEM16A | Chloride channel regulated by IL-4/IL-13 receptor signaling in cholangiocytes | Knockout and knockdown study biliary secretion |
| CD206 | Mannose receptor marking IL-4Rα+ macrophages | Used as a marker in macrophage polarization studies |
| FOXP3 | Transcription factor in regulatory T cells influenced by IL-4 signaling | Knockout models study Treg/Th2 balance |
| GATA3 | Transcription factor driving Th2 differentiation downstream of the complex | Knockout and overexpression study Th2 programs |
How Is interleukin-4 receptor complex Regulated?
Signaling through the interleukin-4 receptor complex is tightly regulated at multiple levels. Ligand availability controls assembly, since IL-4 must bind IL-4Rα before γc or IL-13Rα1 is recruited. Receptor abundance and surface half-life are modulated by internalization and degradation, while SOCS proteins provide negative feedback that terminates JAK/STAT signaling. Phosphatases and ubiquitin ligases further attenuate the pathway, and competition for the shared γc subunit with other cytokine receptors can indirectly tune IL-4 responses. In disease states, persistent activation of the complex sustains STAT6-dependent transcriptional programs that drive inflammation and remodeling.
interleukin-4 receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL4R | Asthma and atopic dermatitis | IL4R knockout and point-mutation cell lines; dupilumab-blockade assays |
| IL13RA1 | Fibrosis and cholangiocyte dysfunction | IL13RA1 knockout cholangiocyte models; TMEM16A readout |
| IL4R | Adverse cardiac remodeling | Macrophage-specific IL4R knockout in ischemic cardiomyopathy models |
| STAT6 | Th2 inflammation and allergic disease | STAT6 knockout T cells and macrophages |
| IL4 | Type 2 inflammation and IgE production | IL4 overexpression and knock-in models |
Asthma and atopic dermatitis
The interleukin-4 receptor complex is central to Th2-driven airway inflammation. IL-4 and IL-13 signaling through the complex promotes IgE class switching, mucus production and airway hyperresponsiveness, and genetic or pharmacological interruption of the pathway reduces allergic inflammation. Dupilumab, a monoclonal antibody that blocks IL-4Rα, is approved for moderate-to-severe atopic dermatitis and asthma, validating GO:0016516 as a therapeutic target.
Fibrosis and cholangiocyte dysfunction
Type II IL-4 receptor complexes on non-immune cells mediate IL-13-driven fibrosis. In cholangiocytes, signaling through IL-4 and IL-13 receptor complexes regulates TMEM16A expression and biliary secretion, linking the complex to cholestatic and fibrotic liver disease. These findings show that GO:0016516 is not restricted to immune cells and can directly control epithelial ion transport.
Adverse cardiac remodeling
CD206+IL-4Rα+ macrophages have been identified as drivers of adverse cardiac remodeling in ischemic cardiomyopathy, indicating that the interleukin-4 receptor complex contributes to maladaptive repair after myocardial infarction. This expands the disease relevance of GO:0016516 beyond classical allergy and highlights macrophage-directed therapeutic opportunities.
Cancer immunology
IL-4 receptor signaling can shape the tumor microenvironment by promoting alternatively activated macrophages and Th2-skewed immune responses. Because the complex is expressed on both immune and tumor cells, its role in cancer is context-dependent, and targeting the pathway requires careful consideration of cell-type-specific effects.
From interleukin-4 receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL-4Rα mediate a specific disease phenotype? | IL4R knockout cell line or animal model |
| Which residues are required for high-affinity IL-4 binding? | IL4R point-mutation knock-in |
| How does a disease-associated IL4R variant alter signaling? | Point-mutation knock-in of the variant |
| Where and when is the complex expressed? | Tagged knock-in of IL4R or IL13RA1 |
| Does overexpression of the complex drive inflammation? | IL4R or IL13RA1 overexpression |
| Which genes are downstream of the complex? | Knockout plus RNA-seq and CRISPR library screening |
How to Study the interleukin-4 receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes downstream of the complex | Defining IL-4/IL-13 target programs |
| Phosphoproteomics | Kinase activation and signaling nodes | Mapping JAK/STAT and PI3K arms |
| Affinity purification mass spectrometry | Subunit composition and interactors | Defining type I vs type II complexes |
| Surface plasmon resonance | Binding affinity and kinetics | Measuring IL-4/IL-4Rα interaction |
| Flow cytometry | Surface receptor expression | Identifying IL-4Rα+ macrophage subsets |
| Immunofluorescence | Subcellular localization | Confirming plasma membrane assembly |
| CRISPR knockout screening | Genes required for complex function | Discovering modifiers of IL-4 signaling |
| Western blot | STAT6 phosphorylation | Readout of pathway activation |
Transcriptomic profiling of receptor activation
RNA-seq after IL-4 stimulation of wild-type and receptor-knockout cells identifies the gene programs controlled by GO:0016516. Comparing IL4R, IL13RA1 and STAT6 knockouts distinguishes type I from type II signaling and reveals shared versus unique target genes.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based phosphoproteomics captures the immediate signaling events triggered by the complex, including JAK and STAT phosphorylation. Affinity purification of tagged receptor subunits followed by mass spectrometry defines the composition and interaction partners of the assembled complex.
Structural and biophysical methods
Crystal structures and surface plasmon resonance measure how IL-4 binds IL-4Rα and how γc or IL-13Rα1 is recruited. These methods guide the design of inhibitors and antibodies that block complex assembly.
Imaging and flow cytometry
Flow cytometry and immunofluorescence detect surface expression of IL-4Rα and γc on immune and non-immune cells. Macrophage markers such as CD206 combined with IL-4Rα staining identify pathogenic populations in tissue.
How CRISPR Can Be Used to Study GO:0016516 interleukin-4 receptor complex
Knockout
CRISPR knockout of IL4R, IL2RG, IL13RA1 or STAT6 eliminates specific subunits of the interleukin-4 receptor complex and provides a clean background to test which ligand responses depend on GO:0016516. Knockout cell lines are widely used to validate antibody specificity and to define downstream transcriptional programs.
Point Mutation
Point-mutation knock-in of residues in IL4R or IL13RA1 that mediate ligand binding or subunit recruitment allows precise structure-function dissection of the complex. Disease-associated variants can be introduced to test whether they alter high-affinity binding or signaling output.
Knock-in
Tagged knock-in of IL4R or IL13RA1 with fluorescent or epitope tags enables visualization and purification of the endogenous complex without overexpression artifacts. Knock-in reporters can also track receptor internalization and recycling in real time.
Overexpression
Overexpression of IL4R, IL13RA1 or their ligands in cell lines amplifies signaling through the complex and is useful for biochemical studies of assembly and downstream activation. Overexpression models also help test whether increased receptor dosage is sufficient to drive inflammatory gene programs.
How EDITGENE Supports interleukin-4 receptor complex Research
Researchers studying interleukin-4 receptor complex-related genes often need to determine whether a candidate gene is causally involved in receptor assembly, signaling or disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services that let you move from correlation to causation with validated, publication-ready reagents.
Contact EDITGENE today to design your custom CRISPR model for interleukin-4 receptor complex research.
Frequently Asked Questions About interleukin-4 receptor complex
What is the interleukin-4 receptor complex?
It is a cell-surface protein complex (GO:0016516) that binds IL-4 and consists of a high-affinity IL-4Rα chain plus the common gamma chain shared with the IL-2 receptor.
What genes are involved in the interleukin-4 receptor complex?
The core genes are IL4R, IL2RG and IL13RA1, with signaling partners including JAK1, JAK3, STAT6, IRS1 and IRS2.
What is the difference between type I and type II IL-4 receptors?
Type I uses IL-4Rα with γc and responds to IL-4, while type II uses IL-4Rα with IL-13Rα1 and responds to both IL-4 and IL-13.
How does IL-4 activate its receptor?
IL-4 first binds IL-4Rα with high affinity, then recruits γc or IL-13Rα1 to form a ternary complex that activates JAK kinases and STAT6.
What diseases are linked to the interleukin-4 receptor complex?
Asthma, atopic dermatitis, fibrosis, cholangiocyte dysfunction and adverse cardiac remodeling have been linked to this complex.
Why is IL-4Rα a drug target?
IL-4Rα is the high-affinity, ligand-specific subunit, and blocking it with dupilumab reduces Th2 inflammation in allergic diseases.
What signaling pathways does the complex activate?
It activates JAK/STAT6 as well as IRS/PI3K/Akt pathways, shaping Th2 differentiation and macrophage polarization.
How can I study the interleukin-4 receptor complex with CRISPR?
Knockout, point-mutation, knock-in and overexpression models can be used to test subunit function, ligand binding and downstream gene programs.
Is the interleukin-4 receptor complex expressed outside immune cells?
Yes, type II complexes are expressed on epithelial and stromal cells, including cholangiocytes and cardiac macrophages.
What is the GO ID for the interleukin-4 receptor complex?
The Gene Ontology ID is GO:0016516, with the synonym IL-4 receptor complex.
Conclusion
The interleukin-4 receptor complex (GO:0016516) is a ligand-driven, heteromeric cell-surface assembly that converts IL-4 and IL-13 signals into JAK/STAT6 and PI3K/Akt outputs. Its subunit composition determines ligand specificity and cell-type responses, and its dysregulation underlies allergic, fibrotic and cardiac disease. Because IL-4Rα is a validated therapeutic target, the complex remains a focus for drug development and mechanistic studies. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal evidence needed to translate receptor biology into new treatments.
References
- 1. Junttila IS. 2018. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes.. Front Immunol 9:888 PMID: 29930549
- 2. Harb H et al.. 2020. Mechanisms of Dupilumab.. Clin Exp Allergy 50(1):5-14 PMID: 31505066
- 3. LaPorte SL et al.. 2008. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system.. Cell 132(2):259-72 PMID: 18243101
- 4. Pan PY et al.. 1999. IL-4 receptor mutations.. Curr Opin Immunol 11(6):615-20 PMID: 10631544
- 5. Wang Q et al.. 2025. CD206(+)IL-4Rα(+) Macrophages Are Drivers of Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.. Circulation 152(4):257-273 PMID: 40308203
- 6. Chatila TA. 2004. Interleukin-4 receptor signaling pathways in asthma pathogenesis.. Trends Mol Med 10(10):493-9 PMID: 15464449
- 7. Ul-Haq Z et al.. 2016. Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box.. Cytokine Growth Factor Rev 32:3-15 PMID: 27165851
- 8. Dutta AK et al.. 2020. Signaling through the interleukin-4 and interleukin-13 receptor complexes regulates cholangiocyte TMEM16A expression and biliary secretion.. Am J Physiol Gastrointest Liver Physiol 318(4):G763-G771 PMID: 32090602
